Video

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

The dose of cetuximab must be precise otherwise it will be difficult for a patient with head and neck cancer to see results, explains Ciccolini.

It needs to be ensured that the drug is at a certain level to exert constant pressure on the target. This makes dose de-escalation difficult with this drug, but it was the best way to see responses, states Ciccolini.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS